This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.00% per year. These returns cover a period from January 1, 1988 through May 4, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
biotechs: Archive
Xenon Pharmaceuticals Stock Gains 22% in Six Months: Here's Why
by Zacks Equity Research
XENE's shares climb 22% in six months as azetukalner delivers strong phase III epilepsy data and advances across multiple late-stage studies.
XENEPositive Net Change LQDAPositive Net Change IMCRPositive Net Change INDVPositive Net Change
biotechs
Definium Stock Soars 50% as Phase III Depression Study Meets Key Goals
by Zacks Equity Research
DFTX stock surges 50% as phase III data show its single-dose, investigational MDD therapy delivers rapid, durable symptom improvements and meets all key goals.
LQDAPositive Net Change IMCRPositive Net Change INDVPositive Net Change DFTXPositive Net Change
biotechnology biotechs medical pharmaceuticals
ABBV Jumps on Deepening Immunology Portfolio With $10.9B APGE Buyout
by Zacks Equity Research
AbbVie shares jump after its $10.9B Apogee deal adds late-stage eczema and respiratory candidates, deepening its immunology pipeline.
REGNPositive Net Change SNYNegative Net Change ABBVPositive Net Change APGENegative Net Change
biotechs medical pharmaceuticals
Regenxbio Shares Rise on Plans to Resubmit Navsunli BLA for MPS II
by Zacks Equity Research
RGNX shares jump after FDA alignment on next steps for Navsunli, paving the way for a planned MPS II BLA resubmission in Q3 2026.
RGNXPositive Net Change DNLIPositive Net Change LQDAPositive Net Change IMCRPositive Net Change
biotechs
Pfizer's Mixed Phase III Data for Sigvotatug Vedotin in NSCLC
by Zacks Equity Research
PFE's phase III NSCLC study misses a key survival goal overall, but a large subgroup shows favorable survival trends vs docetaxel.
PFENegative Net Change MRKPositive Net Change IMCRPositive Net Change INDVPositive Net Change
biotechs
Bull of the Day: Liquidia Corporation (LQDA)
by Ethan Feller
Liquidia Corporation shares have been rallying as the company turns net profitable amid successful drug commercialization.
LQDAPositive Net Change
biotechnology biotechs
Here's Why You Should Add LXRX Stock to Your Portfolio Now
by Zacks Equity Research
Lexicon advances sotagliflozin into new indications while its obesity and pain programs progress, setting the stage for multiple pipeline milestones.
NVONegative Net Change LXRXPositive Net Change VTRSPositive Net Change
biotechs
QURE Announces Initial Data on Gene therapy for Temporal Lobe Epilepsy
by Zacks Equity Research
uniQure reports early AMT-260 epilepsy study data, with three patients showing 79-100% seizure reductions and no serious safety events.
QURENegative Net Change LQDAPositive Net Change IMCRPositive Net Change
biotechnology biotechs medical pharmaceuticals
Can Alnylam's Broader Portfolio Ease Its Dependence on Amvuttra?
by Ahan Chakraborty
Amvuttra is the primary driver of ALNY's revenues, but growth from Givlaari, Oxlumo and Leqvio may help diversify the company's top line.
ALNYPositive Net Change NVSNegative Net Change PFENegative Net Change BBIOPositive Net Change
biotechnology biotechs medical pharmaceuticals
QURE Soars as FDA Backs AMT-130 Data for Accelerated Approval
by Zacks Equity Research
QURE surges after the FDA said AMT-130 phase I/II data could support an accelerated approval filing for Huntington's disease.
QURENegative Net Change LQDAPositive Net Change IMCRPositive Net Change
biotechnology biotechs medical pharmaceuticals